BEVACIZUMAB 1 — Class II drug recall D-1271-2019
Terminated recall by Pacifico National, Inc. dba AmEx Pharmacy, reported 2019-05-08, distributed nationwide. Defective Delivery System: difficult to express
| Recall number | D-1271-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pacifico National, Inc. dba AmEx Pharmacy, Melbourne, FL, United States |
| Recall initiated | 2019-04-19 |
| Classified | 2019-05-07 |
| Reported by FDA | 2019-05-08 |
| Terminated | 2021-02-16 |
| Distributed | Nationwide (US) |
| Quantity | 249 syringes |
| Lot numbers | 190212AB |
| Expiration dates | 2019-05-13 |
Product
BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This biologic product was repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901 Lot:190212AB BUD:5/13/2019, Repackaged on 2/12/2019
Reason for recall
Defective Delivery System: difficult to express
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1271-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.